EP264/#556 Physician-reported patient involvement in 1l ovarian cancer treatment, including maintenance, in the US and Europe: a real-world chart review analysis (2017–2020)

Objectives

Ovarian cancer (OC) treatment options include VEGF inhibitors (VEGFi) and PARP inhibitors (PARPi) as first-line maintenance (1Lm) treatments. There is interest in understanding patient contribution in treatment selection. We describe physician-reported patient involvement in treatment decisions in the 1L setting.

Methods

Retrospective chart review study of electronic medical records (EMRs) in Italy/France/Germany/Spain/UK/US, conducted for patients diagnosed with OC (June 1, 2017–May 31, 2020) in line with Healthcare Market Research guidelines. Eligible oncologists extracted data from EMRs by completing standardized patient record forms (PRFs), including questions on patient involvement in treatment decisions. Data were descriptively summarized.

Results

PRFs for 7072 patients with OC were completed by 416 oncologists; 4986 patients received 1L adjuvant treatment. Higher rates of patient involvement were seen in Germany/UK/US; treatments selected differed when patient input was considered for 1L adjuvant (n=754) or 1Lm treatment (n=521; table 1). Timing of patient involvement in 1L treatment decisions varied (table 2). For 1Lm treatment, most patients (44%) discussed options with their physician at treatment initiation (36%–49% across countries), 16% after surgery, 24% at chemotherapy initiation, and 16% when chemotherapy response was evaluated.

Conclusions

Rates of physician-reported patient involvement in treatment decisions were consistent between 1L (15%) and 1Lm (16%); <50% of patients discussed 1Lm with their physician at treatment initiation, highlighting a need for early discussion with patients. Funding: GSK study OneCDP#214555. Editorial support provided by Fishawack Health, funded by GSK.